The concentrations of two key blood biomarkers for Alzheimer’s disease are affected by some medical conditions, which could potentially lead to misdiagnosis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
Nature Aging Open Access 13 March 2023
-
Association of neurofilament light chain with renal function: mechanisms and clinical implications
Alzheimer's Research & Therapy Open Access 16 December 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
18 July 2022
In the version of this article initially published, there was a typo in the last sentence of the third-to-last paragraph, where in the text now reading “an example is the Cockcroft–Gault equation to estimate renal clearance based on serum creatinine concentration, sex, age, weight, and height,” creatinine originally read “creatine.” The change has been made in the HTML and PDF versions of the article.
References
Teunissen, C. E. et al. Lancet Neurol. 21, 66–77 (2021).
Mielke, M. M. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01822-2 (2022).
Palmqvist, S. et al. JAMA 324, 772–781 (2020).
Thijssen, E. H. et al. Lancet Neurol. 20, 739–752 (2021).
Mielke, M. M. et al. JAMA Neurol. 78, 1108–1117 (2021).
Mielke, M. M. et al. Alzheimers Dement. 18, 602–611 (2022).
Syrjanen, J. A. et al. Alzheimers Dement. https://doi.org/10.1002/alz.12466 (2021).
Barthélemy, N. R., Horie, K., Sato, C. & Bateman, R. J. J. Exp. Med. 217, e20200861 (2020).
Karikari, T. K. et al. Nat. Rev. Neurol. https://doi.org/10.1038/s41582-022-00665-2 (2022).
Cockcroft, D. W. & Gault, M. H. Nephron 16, 31–41 (1976).
Nianogo, R. A. et al. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2022.0976 (2022).
Schindler, S. E. et al. Neurology https://doi.org/10.1212/WNL.0000000000200358 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.E.S. has analysed data on the PrecivityAD blood test provided by C2N Diagnostics. She has not received any research funding or personal compensation from C2N Diagnostics or any other diagnostics or pharmaceutical companies. Washington University may receive royalties from the PrecivityAD blood test. T.K.K. declares no competing interests.
Rights and permissions
About this article
Cite this article
Schindler, S.E., Karikari, T.K. Comorbidities confound Alzheimer’s blood tests. Nat Med 28, 1349–1351 (2022). https://doi.org/10.1038/s41591-022-01875-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01875-3
This article is cited by
-
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Nature Reviews Neurology (2024)
-
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
Nature Aging (2023)
-
Association of neurofilament light chain with renal function: mechanisms and clinical implications
Alzheimer's Research & Therapy (2022)